SADDLE RIVER, N.J. and KENNESAW, Ga., June 3 /PRNewswire-FirstCall/ -- Two leaders in the pharmaceutical contract services industry, PDI, Inc. (Nasdaq: PDII), a provider of sales and marketing support to U.S. pharmaceutical companies, and The Medical Affairs Company (TMAC(R)), the leading provider of customized Medical Science Liaison (MSL) and Medical Affairs services, have signed an agreement aligning their respective services in order to bring clients a more complete set of field-based commercialization solutions.
Under the exclusive agreement, PDI and TMAC will integrate their service offerings to benefit client brands, participate in joint client presentations and exchange new business leads. By operating under this agreement, both PDI and TMAC are better able to meet a wider variety of client demands for best-in-class field resources, while preserving the important separation of pharmaceutical sales and medical departments.
"The MSL plays an increasingly crucial role in pharmaceuticals today - that of providing high-level scientific information to key opinion leaders and other medical doctors on a peer-to-peer basis," said Nancy Lurker, Chief Executive Officer, PDI. "We're very pleased to partner with TMAC through this strategic alliance. TMAC's expertise in providing MSL services to pharmaceutical companies is highly regarded. Our agreement increases PDI's ability to provide maximum value to our clients and fills a critical need for a higher science personal engagement with physicians."
TMAC Chief Executive Officer Evan Demestihas, M.D., believes the agreement will give each company even greater leverage to build their business in a highly competitive industry. "With our partnership, we each gain a more complete suite of field services, and that places us in an even better position to seize growth opportun
|SOURCE PDI, Inc.|
Copyright©2009 PR Newswire.
All rights reserved